Cadonilimab

(Synonyms: AK104)
1 Cited Publications
Kundenbewertung

Based on 1 publication(s) in Google Scholar

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.87%
  • CAS. Nr.: 2394841-59-7
  • Molecular Weight:198.64 kDa
  • Speicherung:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biologische Aktivität
  • Chemical Information
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Cadonilimab

More
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00